Teva loses late attempt to stop generic Copaxone going on sale

Teva (TEVA) has lost a case in which it tried to persuade a court to delay the release of generic forms of Copaxone by saying that more testing was needed for these versions of the multiple-sclerosis drug.

A 20-milligram dosage of Copaxone is due to lose its patent protection on May 24, after which Mylan (MYL) and Novartis (NVS) unit Sandoz can start selling cheaper forms of the treatment.

Teva hopes to switch patients to a longer-lasting 40-milligram regimen, which is protected until 2015.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs